The Center for Narcolepsy is a multidisciplinary research program on the etiology, diagnosis, and treatment of this illness. We have brought together the critical mass of specialists in the necessary fields to advance knowledge in the area and have made very significant progress during the last funding period. A multidisciplinary approach is required because of the prime involvement of several very diverse biological systems in its pathophysiology. First, narcolepsy involves the immune system. The disorder has a very strong HLA association but does not seem to be an autoimmune disease. In the last funding period, we have identified the HLA alleles most likely to be involved and have discovered a new immune related gene that is tightly linked with the pathology in canine narcolepsy. We are therefore now at the point where we will be able to study the mechanisms of action of these genetic factors. Second, narcolepsy is a centrally mediated disorder of REM sleep that is only poorly controlled by available medications. We now have clear indications that the neurochemical defects involve hypersensitive cholinergic systems in the brainstem and the basal forebrain. it will be the over-all goal of the next funding period to understand how these immunogenetic factors interact with key neurotranmitters systems in the brain to produce narcolepsy. The proposed work is divided into four different but very inter-related scientific projects: Human Banking and Diagnosis; Linkage and Molecular Studies in Canines; Evidence for Neuronal Degeneration in Narcolepsy, and Neurochemical Studies of Narcolepsy. These projects involve research using both human material and the only available animal model, canine narcolepsy. This model provides a unique opportunity to study the fundamental neurochemical mechanisms involved in these diseases, and to rapidly test new strategies for treatment that emerge as a result of these investigations. The growing realization of the enormous personal and societal consequences resulting directly or indirectly from sleep pathologies such as narcolepsy mandate a continued investment into research in these diseases.
| Bonvalet, Melodie; Ollila, Hanna M; Ambati, Aditya et al. (2017) Autoimmunity in narcolepsy. Curr Opin Pulm Med 23:522-529 |
| Plante, David T; Finn, Laurel A; Hagen, Erika W et al. (2016) Subjective and Objective Measures of Hypersomnolence Demonstrate Divergent Associations with Depression among Participants in the Wisconsin Sleep Cohort Study. J Clin Sleep Med 12:571-8 |
| Gottlieb, D J; Hek, K; Chen, T-H et al. (2015) Novel loci associated with usual sleep duration: the CHARGE Consortium Genome-Wide Association Study. Mol Psychiatry 20:1232-9 |
| Ollila, Hanna M; Ravel, Jean-Marie; Han, Fang et al. (2015) HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. Am J Hum Genet 96:136-46 |
| Li, Jason; Moore 4th, Hyatt; Lin, Ling et al. (2015) Association of low ferritin with PLM in the Wisconsin Sleep Cohort. Sleep Med 16:1413-1418 |
| Kornum, Birgitte Rahbek; Pizza, Fabio; Knudsen, Stine et al. (2015) Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset. Brain Behav Immun 49:54-8 |
| Kawai, Makoto; O'Hara, Ruth; Einen, Mali et al. (2015) Narcolepsy in African Americans. Sleep 38:1673-81 |
| Holm, Anja; Lin, Ling; Faraco, Juliette et al. (2015) EIF3G is associated with narcolepsy across ethnicities. Eur J Hum Genet 23:1573-80 |
| Jacob, Louis; Leib, Ryan; Ollila, Hanna M et al. (2015) Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun 47:44-57 |
| de Lecea, Luis (2015) Optogenetic control of hypocretin (orexin) neurons and arousal circuits. Curr Top Behav Neurosci 25:367-78 |
Showing the most recent 10 out of 55 publications
